Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01943799 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT01943799 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 178 participants.
The verdict
NCT01943799, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety and efficacy of GS-4774 in adults with chronic hepatitis B (CHB) viral infection who have been virally suppressed with an oral antiviral (OAV) medication.
Interventions
- BIOLOGICAL GS-4774
- DRUG OAV Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2013-09-13 |
| Est. Completion | 2015-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01943799
The ClinicalTrials.gov registry entry for NCT01943799 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GS-4774 is the first listed.
NCT01943799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01943799 about?
NCT01943799 is a clinical study titled "Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B". The primary objectives of this study are to evaluate the safety and efficacy of GS-4774 in adults with chronic hepatitis B (CHB) viral infection who have been virally suppressed with an oral antiviral (OAV) medication.
What is the current status of trial NCT01943799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2013-09-13. Estimated completion is 2015-03-03.
What interventions are being tested in trial NCT01943799?
The interventions under investigation include: GS-4774 (BIOLOGICAL), OAV Regimen (DRUG).
Who is sponsoring clinical trial NCT01943799?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.